RAMESH ELURI: Open Payments
NPI 1497706097 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,448 in 114 payments from 15 companies in 2025. Trend: 2023 $32,187 · 2024 $1,933 · 2025 $10,448
Consulting: $6,325Food & beverage: $2,813Travel & lodging: $1,309
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 21 | $8,386 |
| Otsuka America Pharmaceutical, Inc. | 16 | $477 |
| Janssen Pharmaceuticals, Inc | 18 | $398 |
| ABBVIE INC. | 15 | $312 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $191 |
| Neurocrine BioSciences, Inc. | 6 | $152 |
| Vanda Pharmaceuticals Inc. | 7 | $119 |
| Alkermes, Inc. | 5 | $110 |
| Lundbeck LLC | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
Products named: COBENFY, VRAYLAR, INVEGA SUSTENNA, ABILIFY ASIMTUFII, CAPLYTA, SPRAVATO, ABILIFY MAINTENA, REXULTI.
Industry payments across PA — which companies pay providers there.
